Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | AKT1 | P31749 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | PRKCG | P05129 | 1/20 | 0.50 |
| ▸ | PRKCB | P05771 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | PRKCH | P24723 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.50 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.50 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29244213 | 0.84 | FABP3 (0.45) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL30827581 | 0.84 | FABP3 (0.45) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL30777643 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL29735578 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL9067683 | 0.79 | LMNA (0.54) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL5720514 | 0.75 | SMN1; SMN2 (0.65) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL8874191 | 0.74 | MAPK1 (0.54) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL878627 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL19821623 | 0.73 | SMN1; SMN2 (0.66) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL2118813 | 0.73 | LMNA (0.53) | SMN1; SMN2AKT1LMNAPRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090505-A1 | FLUOROPYRIMIDINE PARTICLES FOR THE TREATMENT OF CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4726038-A1 | EXPRESSION-ADJUSTABLE ENGINEERED RNA MOLECULE | Rinuagene Biotechnology Co., Ltd. (CN) | 2026-04-15 | — | — | EP | claimed |
| WO-2025092866-A1 | MULTIVALENT INFLUENZA MRNA VACCINE | 仁景(苏州)生物科技有限公司 | 2025-05-08 | — | — | WO | claimed |
| WO-2026090505-A1 | FLUOROPYRIMIDINE PARTICLES FOR THE TREATMENT OF CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4726038-A1 | EXPRESSION-ADJUSTABLE ENGINEERED RNA MOLECULE | Rinuagene Biotechnology Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-20260092293-A1 | EXPRESSION-ADJUSTABLE ENGINEERED RNA MOLECULE | RINUAGENE BIOTECHNOLOGY CO., LTD. (CN) | 2026-04-02 | — | — | US | disclosed |
| CN-119874799-A | Lipid compounds and lipid nanoparticle compositions | 仁景(苏州)生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-117946201-B | Lipid compounds and lipid nanoparticle compositions | 仁景(苏州)生物科技有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-117946201-A | Lipid compounds and lipid nanoparticle compositions | 仁景(苏州)生物科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092293-A1 | EXPRESSION-ADJUSTABLE ENGINEERED RNA MOLECULE | METTL16, RNMT, TRDMT1 | SMN1; SMN2 3259/4885AKT1 3976/4885LMNA 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.